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Abstract
Rationale, Aims, and Objectives: Several novel oral anticoagulants (NOACs) are
licensed for atrial fibrillation (AF) treatment in the United Kingdom. We describe the
incidence and mortality from ischaemic stroke and major bleeding in non-valvular
atrial fibrillation (NVAF) patients in England, including treatment patterns before/fol-
lowing introduction of NOACs, healthcare resource utilization (HRU), and costs post-
onset of these events.
Method: Data were extracted from the UK Clinical Practice Research Datalink linked
to Hospital Episode Statistics secondary care and Office for National Statistics
mortality data.
Results: Of 42 966 patients with a first AF record between 2011 and 2016, 9143
patients (21.3%) remained without AF (antiplatelets/antithrombotics) treatment post-
index diagnosis. The proportion of patients receiving aspirin for ≥3 months post-index
declined during the study (50.6%-5.5%), irrespective of CHA2DS2-VASc score, while the
proportion prescribed NOACs increased (2.0%-70.1%). Rates of ischaemic stroke per
1000 patient-years (95% CI) were 9.4 (3.8-15.0) with NOACs, 10.4 (8.0-12.9) with warfa-
rin, 20.1 (16.4-23.8) with aspirin, 21.3 (5.3-37.2) with other antiplatelets and 43.6
(39.3-47.8) in patients without AF prescription. Major bleeding occurred at a similar rate
with different treatments. All-cause mortality rates were 42.8 (31.4-54.3) with NOACs,
46.3 (41.1-51.5) with warfarin, 56.5 (50.5-62.4) with aspirin, 102.2 (76.2-128.3) with
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other antiplatelets and 412.8 (399.6-426.0) with no AF prescription. Mean annual
National Health Service healthcare costs up to 1 year post-index were lowest in patients
receiving aspirin plus other antiplatelets without an event (£6152), and highest in patients
with an event without AF prescriptions (£17 957). By extrapolation, national AF HRU in
the United Kingdom in 2016 was estimated at £8-16 billion annually.
Conclusions: These data provide temporal insights into AF treatment patterns and
outcomes for NVAF patients in England and highlight the need to review higher
stroke risk AF patients not receiving antiplatelet/antithrombotic prescriptions.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia,
with an increasing prevalence due to improved survival rates from
conditions such as ischaemic heart disease as well as an ageing popu-
lation.1 AF is an independent risk factor for stroke and thromboembo-
lism, with an estimated 5-fold higher risk than in the normal
population,2 and is predictive of premature mortality3 and heart fail-
ure.4 The estimated direct cost of AF during 2000 in the United King-
dom, excluding hospitalizations with a secondary AF coding and
nursing home costs, was £459 million (0.88% of the National Health
Service [NHS] expenditure).5
Effective stroke prevention can be achieved with oral anticoagu-
lant (OAC) treatment. In a study conducted using English electronic
health records from 2006 to 2016, the prevalence of AF and OAC use
increased, while rates of hospitalized AF-related stroke declined from
2011 and were significantly associated with the uptake of OACs.6
Despite the publication of numerous guidelines on AF management, a
substantial proportion of eligible patients are undertreated.7 In a sys-
tematic review examining the underuse of OACs in AF, 25 of 29 stud-
ies described undertreatment, with 21 of these reporting treatment
levels <60% (range 19.0%-81.3%) of optimal practice. Patients at
increased risk for stroke with a CHA2DS2-VASc score ≥2 were also
suboptimally treated, with seven of nine studies reporting treatment
levels <70% (range 39.0%-92.3%) of optimal practice.8
Since 2012, a number of novel OACs (NOACs) have been
licensed for AF treatment in the United Kingdom that, unlike warfarin,
do not require prothrombin time/international normalized ratio (INR)
monitoring. The risk of all-cause mortality was lower with NOACs
compared with warfarin (INR 2.0-3.0) in a meta-analysis of 23 random-
ized trials involving 94 656 patients.9 The risk of major/intracranial
bleeding was also reduced with most of the NOACs relative to warfa-
rin, although the NOACs were associated with substantial non-
neurological bleeding risk. In the landmark phase III AF trials, the risk
of gastrointestinal bleeding was higher with rivaroxaban, dabigatran,
and edoxaban at some doses, and similar for apixaban, vs warfarin.9
Data on the long-term costs of ischaemic stroke or bleeding in
non-valvular AF (NVAF), AF in the absence of rheumatic mitral
stenosis, a mechanical or bioprosthetic heart valve or mitral valve
repair10 before and after introduction of NOACs and after guidance
to dissuade mono-prescription of aspirin, have not been investi-
gated. This retrospective study aimed to describe temporal trends in
incidence and mortality from ischaemic stroke and major bleeding in
NVAF patients in England, including patterns of treatment following
availability of NOACs, healthcare resource utilization (HRU), and
costs to the NHS after the onset of these events. This is an observa-
tional study and, given the risk of potential confounding from pre-
scribing behaviour, between-treatment comparisons should be
treated with caution and support hypothesis generation for further
research or bring attention to patients potentially at increased risk.
The value of our results is that they are nationally representative
and take an objective approach to all treatment/non-treatment
options, with unique data linkages that are unavailable in most
healthcare settings.
2 | METHODS
2.1 | Data source
Data were extracted from the UK Clinical Practice Research Datalink
(CPRD), an ongoing primary care database of anonymized general
practitioner (GP) medical records representing ~7% of the UK popula-
tion.11 CPRD data were linked to English Hospital Episode Statistics
(HES) secondary care data and Office for National Statistics (ONS)
mortality data. Patients were identified using the CPRD GOLD data-
base and HES admitted data. HRU data were collected from CPRD
GOLD, HES admitted, outpatient and accident and emergency (A&E)
files.
Prescribing data were recorded in CPRD GOLD, allowing ana-
lyses of the management of patients initially and over time. Over-
the-counter medication use could not be formally captured. Patients
were linked across the datasets using CPRD unique identifiers and
the study team had access to anonymized records. The study proto-
cols were approved by an independent Scientific Advisory
Committee.
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2.2 | Patients
For treatment and mortality, data from January 1, 2011 to June
30, 2016 were included. The AF index period ended on March
31, 2016, due to the limited availability of HES data. The index date
was the first ever AF record in CPRD GOLD or HES (see supporting
information 1).
Patient selection criteria included: a first record of AF during the
study period, ≥364 days of active registration before the index date,
≥18 years of age on the index date and eligible for linkage with
HES/ONS data. Patients with heart valve problems or replacement
before, on or after the index date in CPRD GOLD or HES were
excluded. For each outcome, the first ever record during follow-up
after the index AF was identified.
2.3 | Endpoints
We described baseline patient characteristics, use of OACs and
antiplatelets and the incidence of ischaemic stroke, major bleeding,
and mortality. We also analysed HRU and healthcare costs to the
NHS in patients with/without these events. Patient characteristics of
interest, and potential confounding factors, were: age, sex, ethnicity,
smoking and drinking status, body mass index (BMI), deprivation
(Index of Multiple Deprivation), CHA2DS2-VASc score (stroke risk),
12
HAS-BLED score (bleeding risk),12 comorbidities, medication use, and
frailty.13
Use of OACs was assessed in OAC-naive patients (no exposure in
the 364 days pre-index date) from the time of first AF record to first
OAC prescription. Data of interest were: overall OAC use, OAC use
by drug, calendar year, age, and OAC group (warfarin, NOACs, aspirin,
or other antiplatelets).
Ischaemic stroke or major bleeding was defined as a hospital
record in the HES or a primary care record after the first record of AF
(index date). Mortality rates from ischaemic stroke and major bleeding
from ONS mortality data were estimated overall and by age, sex, and
OAC treatment. Cause of death was ascertained from death certifica-
tion records from ONS and linked HES data. Ischaemic stroke and
major bleeding within 10 days before death date were also recorded
as cause of death.
HRU was measured by the number of GP visits, specialist refer-
rals, laboratory tests, prescriptions, A&E visits and investigations, out-
patient visits, and hospitalizations. Activity was captured using
procedural and visit codes (OPCS codes/GP coding systems in CPRD)
and frequency of visits in each category of interest. NHS costs were
valued in 2015 to 2016 UK pounds using standard sources of unit
costs.14-16
2.4 | Statistical analyses
Continuous variables were summarized as mean, SD, median and
interquartile range (IQR). Categorical variables were reported as
absolute count and percentage of counts in each category. Incidence
rates per 1000 patient-years (PY) were estimated using a generalized
linear model with Poisson distribution (log link), adjusting for age and
sex. Results were stratified by baseline risk scores and the potentially
confounding factors listed above. Mortality was estimated as the
number of deaths divided by the total time at risk, adjusting for age
and sex using a generalized linear model with Poisson distribution.
Altered Lin's regression17 was used to estimate mean healthcare
costs per quarter per patient, up to 1 year after newly diagnosed AF,
as confounding factors (baseline CHA2DS2-VASc score, baseline HAS-
BLED score, and frailty) needed to be controlled. Such methodology is
applicable because detailed cost accumulation information is available
during the follow-up period in the data. As most patients with an
event had their first event within the first 3 months following NVAF
diagnosis, we performed sensitivity analyses to compare results using
different follow-up periods (see supporting information 2).
Different follow-up periods were used for incidence/mortality,
HRU, and costs (HRU and cost analyses did not end at the outcomes
of interest). For incidence/mortality, patients were followed from the
index date until the earliest of one of the outcomes of interest, trans-
fer out of the practice, last data collection or death, whichever
occurred first. For HRU, patients were followed from the index date
up to 3 years until transfer out of the practice, last data collection or
death, whichever occurred first. For cost analyses, patients were
followed from the index date up to 1 year until transfer out of the
practice, last data collection or death, whichever occurred first.
Data are reported in-line with the STROBE checklist for observa-
tional studies (see supporting information 2).
3 | RESULTS
3.1 | Patients
In total, 131 814 patients had their first AF event recorded during
2011 to 2016 (Figure 1). The last day of follow-up was limited to the
end of Q1 2016, due to incomplete HES-CPRD linkage for 2016.
Overall, 62 238 patients (47.2%) were excluded, leaving 69 576
patients (52.8%) with ≥364 days of active registration before the
index date. Applying the inclusion criteria of ≥18 years of age on index
date, and the definition of NVAF on, before or after the index date,
42 966 patients were included in the study. As CPRD coverage repre-
sents ~7% of the UK population (based on the 2013 mid-year UK
population11), extrapolation of this incidence rate would suggest there
may have been 900 000 patients with a new diagnosis of NVAF that
met our study inclusion criteria in the United Kingdom during the
period 2011 to Q1 2016.
3.2 | First AF diagnosis
At the time of first AF diagnosis, the median age of patients included
in our study was 78 years (IQR 69-85), with the majority aged
BAKHAI ET AL. 121
≥65 years (83.6%, n = 35 907; Table 1). The mean (SD) duration of
active registration pre-index date was 13.0 (6.1) years. Most patients
had no prior ischaemic stroke (91.2%, n = 39 204) or major bleeding
(81.3%, n = 34 917) recorded and had high (≥3) CHA2DS2-VASc
scores (45.2%, n = 19 437) with low (≤1) HAS-BLED scores (47.3%,
n = 20 330). Most frequent baseline comorbidities were hypertension
(67.2%, n = 28 871) and renal disease (27.2%, n = 11 700; Table 1).
Commonly used medications were antihypertensives (62.4%,
n = 26 793), statins (40.5%, n = 17 404) and antiplatelets (36.5%,
n = 15 674). Overall, 5.4% of patients (n = 2337) had received antico-
agulant treatment within 90 days prior to their first AF diagnosis.
Treatment-naïve patients with a singular first treatment of
warfarin, NOACs, aspirin or other antiplatelet agent showed a similar
distribution across the low (≤1), intermediate (2), and high (≥3)
CHA2DS2-VASc score categories (Table 1). Most of the patients who
did not receive any AF treatment of interest (warfarin, NOAC, aspirin
or other antiplatelet) post-index (n = 12 375) had a high CHA2DS2-
VASc score. Most patients within this group who were not treatment
naïve (n = 3232) had intermediate (2) or high (≥3) HAS-BLED scores.
Table S1 shows patient characteristics by outcome of the index
event, with notable differences observed between those who died vs
survived. The proportion of females was significantly higher in the
group of AF patients who died vs survived (52.3% vs 46.5%, respec-
tively, P < .0001). Similarly, the proportion of white patients (95.3% vs
90.8%, respectively, P < .0001), frail patients (35.6% vs 19.9%, respec-
tively, P < .0001), or patients with high CHA2DS2-VASc scores (57.8%
vs 37.2%, respectively, P < .0001) was significantly higher among AF
patients who died vs survived an event. The proportion of current
drinkers was significantly lower in the group of AF patients who died
compared with those who survived (16.3% vs 23.1%, respectively,
P < .0001). Likewise, the proportion of obese patients (BMI ≥30;
20.6% vs 31.0%, respectively, P < .0001) or patients with low HAS-
BLED scores (44.5% vs 55.5%, respectively, P < .0001) was signifi-
cantly lower among AF patients who died vs survived an event. The
proportion of patients with peripheral vascular disease, congestive
heart failure, or renal disease who died following an event was higher
compared with those who survived. There were similar proportions of
aspirin-treated patients who died or survived.
3.3 | Treatment for first AF event
Approximately half of all patients (54.1%, n = 23 228) received no AF
treatment within 364 days prior to index date, and around one-third
(31.2%, n = 13 405) started singular AF treatment after index diagno-
sis (Figure 2). First singular AF prescriptions post-index consisted of
warfarin (41.9%, n = 5618), aspirin (38.3%, n = 5128), NOACs (15.0%,
n = 2011), and other antiplatelets (4.8%, n = 648). Overall, 9143
patients (21.3%) remained without any AF antithrombotic or anti-
platelet treatment of interest prescriptions after index diagnosis dur-
ing the follow-up period.
In patients who initiated treatment within 3 months after the
index date and remained on treatment for ≥3 months, the proportion
prescribed aspirin declined from 50.6% (n = 817) in 2011 to 5.5%
(n = 9) in Q1 2016. Similar findings were seen in patients with low and
intermediate/high CHA2DS2-VASc scores. A reduction in the propor-
tion of patients being treated with warfarin was also noted, from
54.7% (n = 705) in 2014 to 22.6% (n = 37) in Q1 2016. Conversely,
the proportion who were prescribed NOACs increased steadily from
2.0% (n = 33) in 2012 to 70.1% (n = 115) in Q1 2016 (Figure 3).
The proportion of patients receiving a first AF prescription who
remained on that medication for ≥3 months ranged from 42.0%
(n = 272) with other antiplatelets to 45.7% (n = 2344) with aspirin,
58.1% (n = 1168) with NOACs and 62.3% (n = 3502) with warfarin
(Figure 4). Rates of prescription stasis were similar between patients
with low or intermediate/high CHA2DS2-VASc scores.
3.4 | Incidence of adverse outcomes and mortality
rates
Among patients who received continued AF treatment in the first
3 months post-index, the sex- and age-adjusted incidence of
ischaemic stroke per 1000 PY (95% confidence interval [CI]) was 9.4
(3.8-15.0) in patients receiving NOACs, 10.4 (8.0-12.9) in those
receiving warfarin, 20.1 (16.4-23.8) in patients receiving aspirin, 21.3
(5.3-37.2) in patients receiving antiplatelets and 43.6 (39.3-47.8) in
those without AF prescription (Table 2). Mortality rates from
F IGURE 1 Patient attrition in the
linked HES-CPRD GOLD. aPatients with
at least one record of valvular disease
before, on or after index date in CPRD
GOLD or HES admitted. AF, atrial
fibrillation; CPRD, UK Clinical Practice
Research Datalink; HES, English Hospital
Episode Statistics; Q, quarter
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TABLE 1 Patient characteristics at the time of first AF diagnosis, by treatment status
Characteristic
Treatment-naïve patients with singular first treatmenta
Patients without treatment of
interest post-index
All AF patients











naïve (n = 3232)
Treatment naïve
(n = 9143)
n % n % n % n % n % n % n %
Sex
Male 22 514 52.4 2957 52.6 1096 54.5 2638 51.4 294 45.4 1632 50.5 4203 46.0
Female 20 452 47.6 2661 47.4 915 45.5 2490 48.6 354 54.6 1600 49.5 4940 54.0
Age at first AF, years
18-34 300 0.7 26 0.5 5 0.2 12 0.2 0 0.0 10 0.3 228 2.5
35-44 568 1.3 88 1.6 29 1.4 61 1.2 3 0.5 14 0.4 307 3.4
45-54 1771 4.1 308 5.5 132 6.6 257 5.0 12 1.9 58 1.8 625 6.8
55-64 4420 10.3 756 13.5 291 14.5 758 14.8 53 8.2 145 4.5 1104 12.1
65-74 9889 23.0 1618 28.8 569 28.3 1364 26.6 139 21.5 522 16.2 1584 17.3
74-84 14 510 33.8 1946 34.6 640 31.8 1492 29.1 227 35.0 1126 34.8 2337 25.6
85+ 11 508 26.8 876 15.6 345 17.2 1184 23.1 214 33.0 1357 42.0 2958 32.4
Mean (SD) 76.0 (12.6) 73.0 (11.8) 72.9 (12.1) 74.3 (12.3) 78.9 (11.0) 81.0 (10.8) 74.5 (16.3)
Median (IQR) 78 (69-85) 75 (66-82) 74 (65-82) 75 (66-84) 80 (71-87) 83 (75-89) 78 (65-87)
Ethnicity
White 39 888 92.8 5174 92.1 1796 89.3 4616 90.0 610 94.1 3093 95.7 8411 92.0
Asian 496 1.2 48 0.9 6 0.3 51 1.0 6 0.9 38 1.2 106 1.2
Black 250 0.6 15 0.3 5 0.2 33 0.6 3 0.5 18 0.6 72 0.8
Other 2332 5.4 381 6.8 204 10.1 428 8.3 29 4.5 83 2.6 554 6.1
Year of first AF
2011 9415 21.9 1193 21.2 32 1.6 1692 33.0 148 22.8 682 21.1 1801 19.7
2012 9593 22.3 1294 23.0 109 5.4 1533 29.9 166 25.6 698 21.6 1843 20.2
2013 8738 20.3 1226 21.8 247 12.3 1088 21.2 138 21.3 642 19.9 1882 20.6
2014 7638 17.8 1119 19.9 537 26.7 568 11.1 115 17.7 586 18.1 1707 18.7
2015 6271 14.6 697 12.4 887 44.1 215 4.2 76 11.7 519 16.1 1512 16.5
2016 Q1c 1311 3.1 89 1.6 199 9.9 32 0.6 5 0.8 105 3.2 398 4.4
Active registrationd pre-index date, years
Mean (SD) 13.0 (6.1) 13.0 (6.0) 13.9 (6.5) 12.9 (5.9) 13.5 (5.9) 13.1 (6.2) 12.6 (6.3)






13.4 (10.0-17.3) 13.1 (9.2-16.9) 12.8 (8.2-16.4)
Active registration post-index date, yearse
Mean (SD) 1.7 (1.4) 2.2 (1.4) 1.3 (1.0) 2.4 (1.5) 2.0 (1.4) 0.3 (0.8) 1.0 (1.3)
Median (IQR) 1.3 (0.4-2.6) 2.0 (1.0-3.1) 1.0 (0.5-1.7) 2.3 (1.2-3.5) 1.8 (0.9-3.1) 0.1 (0.0-0.2) 0.4 (0.1-1.6)
Time to first treatment after AF index, days
Mean (SD) — 67.3 (160.8) 106.6 (243.8) 59.5 (147.7) 118.1 (234.9) — —
Median (IQR) — 18 (5-53) 25 (7-73) 14 (0-42) 31.5 (15-73) — —
Smoking statuse
Current 3504 8.2 377 6.7 140 7.0 364 7.1 43 6.6 319 9.9 788 8.6
Ex 14 208 33.1 1718 30.6 596 29.6 1513 29.5 203 31.3 1114 34.5 2353 25.7
Non 7598 17.7 1065 19.0 393 19.5 972 19.0 109 16.8 492 15.2 1361 14.9
Unknown 17 656 41.1 2458 43.8 882 43.9 2279 44.4 293 45.2 1307 40.4 4641 50.8
(Continues)
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TABLE 1 (Continued)
Characteristic
Treatment-naïve patients with singular first treatmenta
Patients without treatment of
interest post-index
All AF patients











naïve (n = 3232)
Treatment naïve
(n = 9143)
n % n % n % n % n % n % n %
Drinking statuse
Current 9222 21.5 1173 20.9 418 20.8 1009 19.7 101 15.6 632 19.6 1366 14.9
Ex 2849 6.6 285 5.1 85 4.2 247 4.8 37 5.7 273 8.4 479 5.2
Non 998 2.3 102 1.8 35 1.7 107 2.1 20 3.1 92 2.8 221 2.4
Unknown 29 897 69.6 4058 72.2 1473 73.2 3765 73.4 490 75.6 2235 69.2 7077 77.4
BMI, kg/m2
<18.5 1156 2.7 77 1.4 33 1.6 113 2.2 25 3.9 169 5.2 417 4.6
18.5 to < 25 12 432 28.9 1373 24.4 540 26.9 1463 28.5 220 34.0 1127 34.9 3102 33.9
≥25 to < 30 14 486 33.7 1975 35.2 658 32.7 1808 35.3 200 30.9 1003 31.0 2687 29.4
≥30 12 246 28.5 1869 33.3 666 33.1 1391 27.1 157 24.2 740 22.9 1994 21.8
Unknown 2646 6.2 324 5.8 114 5.7 353 6.9 46 7.1 193 6.0 943 10.3
Mean (SD) 27.9 (6.2) 28.8 (6.3) 28.6 (6.4) 28.0 (6.2) 26.9 (6.1) 26.7 (6.3) 26.7 (6.2)






26.3 (22.6-30.1) 25.9 (22.6-29.8) 25.8 (22.6-29.8)
Deprivation
1 (least deprived) 7285 17.0 985 17.5 381 18.9 927 18.1 101 15.6 533 16.5 1598 17.5
2 8910 20.7 1198 21.3 440 21.9 1093 21.3 137 21.1 659 20.4 1893 20.7
3 9015 21.0 1288 22.9 417 20.7 1014 19.8 148 22.8 601 18.6 1932 21.1
4 8136 18.9 968 17.2 316 15.7 958 18.7 141 21.8 702 21.7 1756 19.2
5 9620 22.4 1179 21.0 457 22.7 1136 22.2 121 18.7 737 22.8 1964 21.5
Prior ischaemic stroke event
No 39 204 91.2 5525 98.3 1973 98.1 5044 98.4 590 91.0 2704 83.7 8917 97.5
Yes 3762 8.8 93 1.7 38 1.9 84 1.6 58 9.0 528 16.3 226 2.5
Prior major bleeding event
No 34 917 81.3 4796 85.4 1721 85.6 4364 85.1 517 79.8 2441 75.5 7480 81.8
Yes 8049 18.7 822 14.6 290 14.4 764 14.9 131 20.2 791 24.5 1663 18.2
CHA2DS2-VASc score
e
Low (≤1) 10 953 25.5 1927 34.3 740 36.8 1749 34.1 134 20.7 336 10.4 2823 30.9
Intermediate (2) 12 576 29.3 1736 30.9 597 29.7 1505 29.3 184 28.4 913 28.2 2311 25.3
High (≥3) 19 437 45.2 1955 34.8 674 33.5 1874 36.5 330 50.9 1983 61.4 4009 43.8
Mean (SD) 2.3 (1.3) 1.9 (1.2) 1.9 (1.2) 2.0 (1.2) 2.5 (1.3) 2.9 (1.3) 2.1 (1.3)
Median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 2 (1-3) 3 (2-3) 3 (2-3) 2 (1-3)
HAS-BLED scoree
Low (≤1) 20 330 47.3 4323 76.9 1569 78.0 3995 77.9 450 69.4 441 13.6 6716 73.5
Intermediate (2) 16 268 37.9 1107 19.7 378 18.8 965 18.8 146 22.5 1730 53.5 1945 21.3
High (≥3) 6368 14.8 188 3.3 64 3.2 168 3.3 52 8.0 1061 32.8 482 5.3
Mean (SD) 1.6 (0.9) 1.1 (0.7) 1.1 (0.7) 1.1 (0.7) 1.3 (0.8) 2.3 (0.9) 1.1 (0.8)
Median (IQR) 2 (1-2) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-2) 2 (2-3) 1 (1-2)
Frailty
No 31 170 72.5 4769 84.9 1649 82.0 4158 81.1 474 73.1 1839 56.9 6170 67.5
Yes 11 796 27.5 849 15.1 362 18.0 970 18.9 174 26.9 1393 43.1 2973 32.5
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TABLE 1 (Continued)
Characteristic
Treatment-naïve patients with singular first treatmenta
Patients without treatment of
interest post-index
All AF patients











naïve (n = 3232)
Treatment naïve
(n = 9143)
n % n % n % n % n % n % n %
Baseline comorbidity
Myocardial infarction 6120 14.2 132 2.3 32 1.6 155 3.0 50 7.7 737 22.8 254 2.8
Cerebrovascular
accident, stroke
5848 13.6 174 3.1 87 4.3 157 3.1 85 13.1 825 25.5 434 4.7
Ischaemic 3762 8.8 93 1.7 38 1.9 84 1.6 58 9.0 528 16.3 226 2.5
Haemorrhagic 131 0.3 6 0.1 6 0.3 10 0.2 2 0.3 13 0.4 23 0.3
Unspecified 4225 9.8 119 2.1 59 2.9 94 1.8 52 8.0 614 19.0 317 3.5
Peripheral vascular
disease
3374 7.9 142 2.5 34 1.7 114 2.2 27 4.2 513 15.9 352 3.8
CHF 4336 10.1 246 4.4 81 4.0 192 3.7 34 5.2 605 18.7 622 6.8
Hypertension 28 871 67.2 3363 59.9 1167 58.0 2894 56.4 429 66.2 2526 78.2 4958 54.2
Diabetes 8268 19.2 732 13.0 289 14.4 613 12.0 112 17.3 827 25.6 1220 13.3
Moderate/severe
liver disease
414 1.0 41 0.7 16 0.8 27 0.5 5 0.8 46 1.4 123 1.3
Renal disease 11 700 27.2 1079 19.2 337 16.8 938 18.3 175 27.0 1278 39.5 2041 22.3
Hospitalization due
to
Malignancies 5544 12.9 556 9.9 194 9.6 457 8.9 63 9.7 697 21.6 1541 16.9
GI bleeding 2519 5.9 229 4.1 73 3.6 214 4.2 43 6.6 262 8.1 634 6.9
Baseline treatmentf
Anticoagulants 2337 5.4 24 0.4 8 0.4 10 0.2 2 0.3 293 9.1 67 0.7
Oral 2128 5.0 0 0.0 0 0.0 0 0.0 0 0.0 252 7.8 0 0.0
Other 310 0.7 24 0.4 8 0.4 10 0.2 2 0.3 55 1.7 67 0.7
Antiarrhythmics 720 1.7 61 1.1 13 0.6 27 0.5 4 0.6 52 1.6 133 1.5
Statins 17 404 40.5 1411 25.1 499 24.8 1132 22.1 177 27.3 1707 52.8 1603 17.5
Antiplatelets 15 674 36.5 0 0.0 0 0.0 0 0.0 0 0.0 2117 65.5 0 0.0
Aspirin 13 483 31.4 0 0.0 0 0.0 0 0.0 0 0.0 1808 55.9 0 0.0
Clopidogrel 3074 7.2 0 0.0 0 0.0 0 0.0 0 0.0 375 11.6 0 0.0
Other 681 1.6 0 0.0 0 0.0 0 0.0 0 0.0 112 3.5 0 0.0
Antidiabetics 5487 12.8 475 8.5 179 8.9 356 6.9 73 11.3 546 16.9 752 8.2
Oral 4814 11.2 441 7.8 163 8. 320 6.2 66 10.2 462 14.3 650 7.1
Insulin 1373 3.2 85 1.5 33 1.6 68 1.3 16 2.5 160 5.0 181 2.0
Other injectable 107 0.2 9 0.2 6 0.3 10 0.2 1 0.2 8 0.2 9 0.1
Antihypertensives 26 793 62.4 3177 56.6 1086 54.0 2567 50.1 355 54.8 2207 68.3 3902 42.7
Beta-blockers 10 497 24.4 907 16.1 328 16.3 687 13.4 117 18.1 923 28.6 1126 12.3
Diuretics 6713 15.6 1052 18.7 309 15.4 875 17.1 110 17.0 416 12.9 1078 11.8
Calcium channel
blockers
11 596 27.0 1481 26.4 491 24.4 1202 23.4 161 24.8 892 27.6 1676 18.3
ARB 5568 13.0 745 13.3 266 13.2 485 9.5 76 11.7 391 12.1 717 7.8
ACE inhibitors 12 318 28.7 1359 24.2 455 22.6 1114 21.7 145 22.4 1016 31.4 1621 17.7
Other
(centrally-acting)
482 1.1 74 1.3 25 1.2 52 1.0 9 1.4 33 1.0 45 0.5
NSAIDs 3218 7.5 533 9.5 181 9.0 459 9.0 50 7.7 205 6.3 737 8.1
(Continues)
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ischaemic stroke were 1.1 (0.3-1.8) with warfarin, 1.4 (0.0-3.3) with
NOACs, 2.5 (1.3-3.7) with aspirin, 5.1 (0.0-11.3) with other
antiplatelets, and 19.5 (16.7-22.4) for patients without AF
prescription.
The incidence rates of major bleeding per 1000 PY (95% CI) were
35.0 (23.7-46.2) in patients receiving NOACs, 32.1 (27.6-36.7) in
patients receiving warfarin, 29.1 (24.2-33.9) in those on aspirin, 31.4
(14.2-48.5) in patients on antiplatelets, and 84.1 (77.4-90.8) in
patients not prescribed any AF treatment during the first 3 months
post-index. The risk of mortality from major bleeding was 11.0
(1.7-20.2) in patients on other antiplatelet therapy and 2.5 (0.00-5.4)
in patients receiving NOACs (Table 2).
All-cause mortality rates per 1000 PY (95% CI) were 42.8
(31.4-54.3) with NOACs, 46.3 (41.1-51.5) with warfarin, 56.5
(50.5-62.4) with aspirin, 102.2 (76.2-128.3) in those on other
antiplatelets, and 412.8 (399.6-426.0) in the cohort with no AF treat-
ment for the first 3 months (Table 2).
Differences in baseline risk scores and confounding factors were
addressed by stratified analysis of incidence rates (Figure 5). A fully
adjusted model was not performed due to the very small number or zero
events for some subgroups. Patients with low baseline CHA2DS2-VASc
scores had low rates of ischaemic stroke, irrespective of treatment post-
index. Patients with intermediate CHA2DS2-VASc scores receiving OACs
had lower rates of ischaemic stroke than those not receiving OACs.
3.5 | Health resource utilization and costs
Up to 3 years after first AF diagnosis, 48.1% of patients (n = 20 668)
survived without ischaemic stroke/major bleeding, 3.5% survived a
TABLE 1 (Continued)
Characteristic
Treatment-naïve patients with singular first treatmenta
Patients without treatment of
interest post-index
All AF patients











naïve (n = 3232)
Treatment naïve
(n = 9143)
n % n % n % n % n % n % n %
Corticosteroids 4496 10.5 552 9.8 188 9.3 394 7.7 55 8.5 520 16.1 1023 11.2
PPIs 14 536 33.8 1462 26.0 537 26.7 1171 22.8 213 32.9 1441 44.6 2723 29.8
HIV drugs 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Antifungals 759 1.8 69 1.2 25 1.2 52 1.0 8 1.2 121 3.7 204 2.2
Note: HAS-BLED score ranges from 0 to 8 as labile INR information was not available.
Abbreviations: ACE, angiotensin-converting-enzyme; AF, atrial fibrillation; ARB, angiotensin-2 receptor blocker; BMI, body mass index; CHF, congestive
heart failure; GI, gastrointestinal; HIV, human immunodeficiency virus; INR, international normalized ratio; IQR, interquartile range; NOAC, novel oral anti-
coagulant; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; Q, quarter; SD, standard deviation.
aAF patients without any study treatments within 364 days prior to index and with at least one prescription of study treatment post-index.
bIncluding clopidogrel.
cAF index date is up to 2016 Q1, while treatment follow-up is up to 2016 Q2.
dActive registration is up to 2016 Q2.
eWithin 364 days prior to index date.
fAt least one prescription for treatment of interest within 90 days prior to index.
F IGURE 2 Patients with first AF
diagnosis by treatment status. aExcludes
680 patients with multiple treatment in
the first prescription. bNOACs include
apixaban, dabigatran, edoxaban, and
rivaroxaban. AF, atrial fibrillation; CPRD,
UK Clinical Practice Research Datalink;
HES, English Hospital Episode Statistics;
NOAC, novel oral anticoagulant

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 2 Sex- and age-adjusted incidence ratea of ischaemic stroke and major bleeding events in NVAF patients remaining on the same initial treatment for 3 consecutive months, by treatment
status
Event


















(95% CI) Events, nb (%)




















































1.1 (0.3-1.8) 8/3502 (0.2) 2.5 (1.3-3.7) 16/2344
(0.7)










11.0 (1.7-20.2) 6/272 (2.2) 24.2 (21.0-27.5) 221/9143
(2.4)
Abbreviations: AF, atrial fibrillation; CI, confidence interval; NOAC, novel oral anticoagulant; NVAF, non-valvular atrial fibrillation.
aIncidence rate per 1000 patient-years of follow-up (reference: patients without event of interest at index diagnosis).














those who survived multiple events and 16.8 (17.2) for those who
died due to an event.
Total adjusted mean NHS costs were highest for AF patients up
to 1 year post-index, with similar costs for patients incurring
ischaemic stroke and major bleeding (Table 4). During this time,
healthcare costs (95% CI) were highest overall for patients with fatal
ischaemic stroke or major bleeding [£17 966 (17 427-18 614)] or
other fatal events [£16 955 (16 497-17 337)], with costs mainly
driven by inpatient admissions and procedures. Sensitivity analyses
capturing costs across different follow-up periods (ie, from first event
vs first NVAF diagnosis) revealed no statistically significant differ-
ences (data not shown). While most patients had their first index
event within 3 months following index diagnosis, some events,
specifically major bleeding, occurred after 12 months of follow-up and
were not included in the cost comparisons.
By treatment group (adjusting for the confounders of baseline
CHA2DS2-VASc score, baseline HAS-BLED score, and frailty only),
mean annual NHS costs of healthcare (95% CI) up to 1 year post-
index were lowest in AF patients receiving aspirin plus other
antiplatelets without an event [£6152 (5820-6200)], and highest in AF
patients without any prescribed AF treatment either with [£17 957
(16 927-18 270)] or without an event [£9803 (9542-10 080)]
(Table 5). The number of patients with an event who did not receive
AF treatment (n = 852) was considerably higher than the number of
patients with an event who were treated with warfarin or a NOAC
(n = 248) or aspirin or other antiplatelets (n = 206).
F IGURE 5 Event incidence rates by treatment and risk scores. NOAC, novel oral anticoagulant
F IGURE 6 AF patients by event
status up to 3 years after first diagnosis.
aExcluded 987 patients with AF index
date in 2016 due to lack of linked data in
2016. AF, atrial fibrillation; CPRD, UK
Clinical Practice Research Datalink; HES,
English Hospital Episode Statistics
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TABLE 3 Unadjusted resource utilization in NVAF patients with or without ischaemic stroke or major bleeding events up to 3 years from AF
index datea
Resource
Resource use, monthly frequency count/patient; Mean (SD); Median (IQR)
Survived, no
event
(n = 20 668)
Survived, single
ischaemic stroke
event (n = 606)
Survived, single
major bleeding














Mean (SD) — 5.6 (9.0) 10.4 (10.3) 5.2 (8.7) — 4.2 (7.5)
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TABLE 3 (Continued)
Resource
Resource use, monthly frequency count/patient; Mean (SD); Median (IQR)
Survived, no
event
(n = 20 668)
Survived, single
ischaemic stroke
event (n = 606)
Survived, single
major bleeding









































































Abbreviations: A&E, Accident & Emergency; AF, atrial fibrillation; HES, English Hospital Episode Statistics; INR, international normalized ratio; IQR, inter-
quartile range; NVAF, non-valvular atrial fibrillation; SD, standard deviation.
aPatients are followed from index NVAF diagnosis up to 3 years, death or end of active registration.
TABLE 4 Mean NHS costs in NVAF patients with or without ischaemic stroke or major bleeding event up to 1 year post-index,a adjusted by
CHA2DS2-VASc score, HAS-BLED score, and frailty
Time
post-index
Mean cost/patient, £ (95% CI)b
Survived,
no event
(n = 20 668)
Survived, single
ischaemic stroke
event (n = 606)
Survived, single
major bleeding








































































0-3 mo £211 £206 £219 £254 £411 £330
4-6 mo £217 £210 £266 £302 £355 £328
7-9 mo £224 £203 £258 £305 £357 £317
10-12 mo £229 £212 £269 £343 £356 £353
Total £881 £831 £1012 £1204 £1478 £1327
[Correction added on 27 April 2020, after first online publication: Table 4 was amended as the alignment of 2 rows were incorrect. The data remains
unchanged.]
Abbreviations: CI, confidence interval; NHS, National Health Service; NVAF, non-valvular atrial fibrillation.
aPatients are followed from index NVAF diagnosis up 1 year, death or end of active registration. As most patients with an event had their first event within
the first 3 months post-NVAF diagnosis, we performed sensitivity analyses to compare results using different follow-up periods, but the findings were not
significantly different.
bCosts are valued in 2015-2016 UK pounds.
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4 | DISCUSSION
Our retrospective study investigated treatment patterns, incidence,
mortality, and long-term costs in a cohort of newly diagnosed NVAF
patients representative of the United Kingdom population before and
following uptake of the NOACs and reduction of aspirin mon-
otherapy. Using linked HES-CPRD GOLD, we identified 42 966
patients [median age 78 years (IQR 69-85)] with a first AF event dur-
ing the period 2011 to Q1 2016.
In line with treatment guidance, we identified a decline in patients
receiving aspirin for ≥3 months post-index from 50.6% to 5.5%,
irrespective of CHA2DS2-VASc score, with an increase in patients pre-
scribed NOACs from 2.0% to 70.1%. Similar findings were reported in
the GARFIELD-AF registry in very recently diagnosed NVAF
patients.18 Increased NOAC use was also reported in European
patients in the GLORIA-AF registry, with 52.4% receiving NOACs
from 2011 to 2014.19 Similar trends, with a smaller proportion of
untreated patients, were reported in a large cross-sectional report of
NVAF patients eligible for OAC therapy during 2012 to 2016.20
Noting the methodological limitation that it is challenging in an
observational dataset to fully adjust for prescribing behaviour con-
founders, we found that patients prescribed NOACs, warfarin, aspirin,
or other antiplatelets had a markedly lower incidence of ischaemic
stroke than patients not prescribed any AF treatment. The reasons for
non-prescription of AF medication in a large number of patients
(n = 9143; 21% of the study cohort) requires exploration. Specific
baseline characteristics may have played a role in this, for example,
patients not receiving AF treatment were concentrated in groups with
high CHA2DS2-VASc scores, as previously reported.
8 Furthermore,
within this group, those who were not treatment naïve tended to have
intermediate/high HAS-BLED scores. While this may reflect older
patients with considerable comorbidities, it could also represent
patients on dialysis or with haematological or other malignancies (9%-
10% with malignancies treated vs. 17% untreated patients). Excluding
patients with low CHA2DS2-VASc scores, who are ineligible for AF
treatment, 6320 patients (15%) remained without appropriate pre-
scribed AF treatment following index diagnosis. The proportion of
these patients steadily increased across each study year (2012,
19.2%; 2013, 21.5%; 2014, 22.3%; 2015, 24.1%). Over-the-counter
recommendations to take aspirin could not be captured in our dataset
and may also be a limiting factor.
Major bleeding occurred at a similar rate across the different
OAC groups, but the highest incidence was in patients not prescribed
any AF treatment during the first 3 months post-index (Table 2). It
may be that the bleeding risk in these patients, for example, from gas-
trointestinal or cancer-related bleeding, contraindicated such
treatments.
The high mortality rate observed in the untreated AF patients
may suggest a potential health gain if selected subgroups were con-
sidered for appropriate OAC therapy. Within our study, ~15% of
patients were not prescribed anticoagulants or antithrombotics in pri-
mary care, which could represent >90 000 patients if extrapolated
nationally.
The use of propensity score matching to model costs within each
treatment group was not planned in the study proposal, but the main
drivers of treatment choice, or of no treatment (baseline CHA2DS2-
VASc score, baseline HAS-BLED score and frailty), were included in the
adjusted cost models. HRU was higher in patients who died compared
with survivors. Healthcare costs were also highest for patients who died
as a result of index/non-index events. The high cost was driven by inpa-
tient admissions and procedures for both groups with fatal events.
Mean NHS healthcare costs up to 1 year post-index were highest in
TABLE 5 Mean NHS costs in NVAF patients by treatment group with or without ischaemic stroke or major bleeding event up to 1 year
post-index,a adjusted by CHA2DS2-VASc score, HAS-BLED score, and frailty
Time
post-index






event (n = 248)
Aspirin + other
antiplatelet,
no event (n = 1829)
Aspirin + other
antiplatelet, with



































































Abbreviations: CI, confidence interval; NHS, National Health Service; NOAC, novel oral anticoagulant; NVAF, non-valvular atrial fibrillation.
aPatients are followed from index NVAF diagnosis up to 1 year, death or end of active registration. As most patients with an event had their first event
within the first 3 months post-NVAF diagnosis, we performed sensitivity analyses to compare results using different follow-up periods, but the findings
were not significantly different.
bCosts are valued in 2015-2016 UK pounds.
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untreated AF patients with/without an event, again emphasizing the
importance of focusing on this patient subgroup. Overall, total mean
costs were highest for AF patients within the first 3 months post-index.
If the prevalence of AF in the United Kingdom is considered to be
900 000 in 2016,6 then the overall burden of management of AF
patients with/without an event would relate to an annual cost between
£9000 and £18 000, which would equate to between £8.1 and £16.2
billion, respectively, even without accounting for societal costs.
These findings add to published data on long-term HRU associ-
ated with stroke and bleeding. In 25 465 US NVAF patients studied
between 1999 and 2009, the most significant costs of first ischaemic
stroke/major bleeding occurred in the first year, but total healthcare
costs remained elevated up to 3 years post-event.21 The considerable
economic burden of ischaemic stroke in AF patients was also
highlighted in a systematic review including 16 studies of ischaemic
stroke costs and HRU in patients with AF across nine countries.22 In
agreement with our results, the major component of overall costs was
hospitalization.
The CPRD has been widely used to study incidence/mortality of
AF in the United Kingdom.20,23-25 Boggon et al described HRU and
outcomes among 15 373 AF patients and age- and sex-matched con-
trols from 2001 to 2006.23 Gallagher et al examined the incidence of
cardiovascular/bleeding outcomes and mortality among 16 513
patients with a first AF diagnosis between 2005 and 2010, before the
launch of the NOACs.24 Our study followed a similar design to the
Gallagher trial; of note, the mean/median age at AF diagnosis
increased by 2 years between the studies (mean 74 years, median
76 years24). More recently, Durham et al published findings of a
cohort study of 23 018 AF patients treated from 2010 to 2014,25
while Lacoin et al reported findings from a large cohort study of NVAF
patients receiving OACs between 2012 and 2016.20 In the Lacoin
study, ~15% of patients were not offered any AF treatment within
90 days pre-index, which remained relatively stable across each study
year. Their inclusion criteria differed from ours and they excluded
patients with low CHA2DS2-VASc scores. Furthermore, they did not
follow up patients after index or present HRU data, but focused on
cross-sectional treatment pattern changes.
The size, breadth of data, representativeness of patient and prac-
tice characteristics, and long-term follow-up are key strengths of the
CPRD, along with the recording of secondary care referrals, thereby
providing a virtually complete medical history.11 Strengths of our
study include its size and duration of active registration pre-index
[mean (SD) 13.0 (6.1) years]. As prescribing data were recorded, we
were able to provide the first temporal data set relating to NOAC use
in NVAF patients in England with relationships to outcomes and HRU.
Our results were internally validated, with healthcare costs increasing
as the number of events occurred, and the number of events increas-
ing by CHA2DS2-VASc score, despite treatment. Additionally, unlike
other registries specific to anticoagulation prescribing, our dataset
includes AF patients on no treatment in significant proportion.
There are some limitations of the CPRD to consider. The quality
of diagnoses represents real-world practice, which might not reflect
the robustness of clinical trials or registry studies. Our analyses were
not adjusted for all potential confounders, which means that compari-
son of outcomes between different treatments should be interpreted
with caution. This is further emphasized by the fact that studies that
attempted to adjust for multiple confounders found a significant pro-
portion of patients were effectively excluded due to non-overlap of
patient characteristics.26,27 Results relating to the use of medication
rely on an assumption that prescribed medications have complete
adherence, which is unlikely. As the coding of outpatient and A&E
operations and procedures is not mandatory in HES, these costs may
have been poorly recorded. Furthermore, the extent of missing data is
unknown, although GP records are expected to be of good quality.
Cost analyses are based on applying the NHS reference unit costs to
the HRU observed in the data and noting that non-NHS societal and
private care costs are not captured.
In conclusion, data from this large, nationally representative study
linking numerous datasets provide valuable insights into current treat-
ment/non-treatment patterns and outcomes for NVAF patients and
their economic impact, proving public health and policy makers ample
examples of temporal changes over time. Our findings emphasize the
major achievements in the United Kingdom of reducing antiplatelet
prescriptions for high-risk AF patients with an increase in OAC use
and the pressing need to review high-risk AF patients not receiving
any antithrombotic or antiplatelet prescriptions for stroke reduction,
as they have a disproportionately high adverse event rate and may
benefit from a multidisciplinary review or be the subject of future pro-
spective registries or trials.
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